Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations
Author:
Publisher
Elsevier BV
Subject
Pharmaceutical Science
Reference34 articles.
1. Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials;Alberts;Semin. Oncol.,2004
2. Recent advances in stealth coating of nanoparticle drug delivery systems;Amoozgar;Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.,2012
3. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice;Bally;Cancer Chemother. Pharmacol.,1994
4. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer;Batist;J. Clin. Oncol.,2001
5. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome;International Journal of Pharmaceutics;2024-11
2. PBPK model of pegylated liposomal doxorubicin to simultaneously predict the concentration–time profile of encapsulated and free doxorubicin in tissues;Drug Delivery and Translational Research;2024-08-05
3. Exploring Contemporary Breakthroughs in Utilizing Vesicular Nanocarriers for Breast Cancer Therapy;Therapeutic Delivery;2024-03-22
4. Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives;Translational Breast Cancer Research;2024-01
5. Liposomal‐encapsulated doxorubicin supercharge‐containing front‐line treatment improves response rates in primary mediastinal large B‐cell lymphoma and mediastinal gray zone lymphoma;Hematological Oncology;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3